Previous preclinical studies indicate that fluorocoxib A has demonstrated to be highly specific and selective for detection of Cox-2-expressing head and neck, bladder, non-melanoma skin, and colorectal cancers [31–34]. This evidence concerns the gene PTGS2 and colorectal cancer.